• Recruiting

NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM

Updated: May 23

NCT04776395



Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma


This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of cancer. Giving iberdomide with dexamethasone my improve time to progression to symptomatic myeloma with improved tolerability.


Sponsor:

Emory University


Collaborators:

Bristol-Myers Squibb

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT04776395


Official Title: Iberdomide in Intermediate- and High-Risk Smoldering Myeloma (SMM) Patients: A Phase 2 Study With a Safety Run-in


First Posted : March 1, 2021


Click here to see details on ClinicalTrials.gov

 

CC-220 - Iberdomide


Emory University Hospital/Winship Cancer Institute

 

- Georgia: Emory University Atlanta






Posts Archive